Arrowhead Pharmaceuticals (ARWR) Change in Account Payables (2010 - 2026)

Arrowhead Pharmaceuticals (ARWR) has 17 years of Change in Account Payables data on file, last reported at -$2.2 million in Q1 2026.

• Quarterly Change in Account Payables rose 54.24% year-over-year to -$2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.1 million (up 1734.29% YoY) and the FY2025 annual result came in at $6.3 million, up 213.55% from the prior year.
• Change in Account Payables fell to -$2.2 million in Q1 2026, from $15.3 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $28.0 million in Q3 2023 to a low of -$15.4 million in Q3 2025.
• A 5-year average of $2.7 million and a median of -$1.7 million in 2023 frame the typical range for Change in Account Payables.
• Annual changes were most pronounced in 2022 — Change in Account Payables soared 1284.53% — and 2023, when it tumbled 501.5%.
• Tracing ARWR's Change in Account Payables over 5 years: stood at -$2.1 million in 2022, then plunged by 501.5% to -$12.5 million in 2023, then surged by 124.62% to $3.1 million in 2024, then surged by 397.33% to $15.3 million in 2025, then tumbled by 114.35% to -$2.2 million in 2026.
• The last three Change in Account Payables figures came in at -$2.2 million (Q1 2026), $15.3 million (Q4 2025), and -$15.4 million (Q3 2025), per Business Quant data.